Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib

Author： Kwon Whi-An Cho In-Chang Yu Ami Nam Byung-Ho Joung Jae Seo Ho Lee Kang Chung Jinsoo

Publisher： Springer Publishing Company

ISSN： 1068-9265

Source： Annals of Surgical Oncology, Vol.20, Iss.13, 2013-12, pp. : 4397-4404

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

By Miyake Hideaki

International Journal of Clinical Oncology, Vol. 18, Iss. 2, 2013-04 ,pp. : 220-225

Springer Publishing Company

Access to resources Recommend Favorite

Sunitinib for metastatic renal cell carcinoma

By Mukherji Deborah Larkin James Pickering Lisa

Future Oncology, Vol. 6, Iss. 9, 2010-09 ,pp. : 1377-1385

Future Medicine

Access to resources Recommend Favorite

Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy

Oncology Letters, Vol. 8, Iss. 2, 2014-01 ,pp. : 881-885

Spandidos Publications

Access to resources Recommend Favorite

Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib

By Szmit Sebastian Nurzynski Pawel Szaluś Norbert Opolski Grzegorz Szczylik Cezary

Acta Oncologica, Vol. 48, Iss. 6, 2009-08 ,pp. : 921-925

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients

By Kim Hye Park Hyung Kwon Woo Lee Ji Tanigawara Yusuke Lim Sun Kim Hyo Shin Sang Ahn Jung Rha Sun

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 4, 2013-10 ,pp. : 825-835

Springer Publishing Company

Access to resources Recommend Favorite